Free Trial

Chris Howerton Analyst Performance

Analyst at Jefferies Financial Group

Chris Howerton is a stock analyst at Jefferies Financial Group in the medical sector, covering 12 publicly traded companies. Over the past year, Chris Howerton has issued 3 stock ratings, including buy and hold recommendations. While full access to Chris Howerton's proprietary MarketBeat Analyst Ranking is reserved for MarketBeat All Access subscribers, the rating is updated daily to reflect the most recent analyst activity. This profile highlights Chris Howerton's coverage history, rating activity, and performance tendencies — helping individual investors make more informed trading decisions.

Analyst Rankings, Coverage, and Performance Statistics

Average Return
00.00% 12-Month ROI
Success Rate
00.00% Profitable Ratings
Total Ratings
30 Last 10 Years
Buy Recommendations
86.67% 26 Buy Ratings
Companies Covered
12 Unique Companies

Ratings Distribution

RatingPercentageCount
Strong Buy0.0%0 ratings
Buy86.7%26 ratings
Hold13.3%4 ratings
Sell0.0%0 ratings

Out of 30 total stock ratings issued by Chris Howerton at Jefferies Financial Group, the majority (86.7%) have been Buy recommendations, followed by 13.3% Hold.

Exchange Coverage

ExchangePercentageCount
NASDAQ
91.7% of companies on NASDAQ
11 companies
OTCMKTS
8.3% of companies on OTCMKTS
1 company

Chris Howerton, an analyst at Jefferies Financial Group, currently covers 12 companies listed on NASDAQ and OTCMKTS, with the majority traded on NASDAQ.

Coverage Focus

Sector IconSectorPercentage
Medical
12 companies
100.0%

Chris Howerton of Jefferies Financial Group specializes in stock coverage within the Medical sector.

Coverage Industries

IndustryPercentage
MED - BIOMED/GENE
9 companies
75.0%
MED - DRUGS
2 companies
16.7%
PHARMACEUTICAL PREPARATIONS
1 company
8.3%

Chris Howerton's Ratings History at Jefferies Financial Group

Recommendation ROI is the percentage between the price on the Report Date to the price 12 months after the report date.
Available with a MarketBeat All Access Subscription
12-Month ROIUpgrade to All Access to use the All ROI Filter
CompanyReport DateActionReport Date Price12-Month
Price Target
Rating12-Month
Price & ROI
Details
Vanda Pharmaceuticals Inc. stock logo
VNDA
Vanda Pharmaceuticals
12/31/2025Boost Price Target$7.03$7.50Hold
Structure Therapeutics Inc. Sponsored ADR stock logo
GPCR
Structure Therapeutics
12/11/2025Set Price Target$67.63$125.00Buy
Structure Therapeutics Inc. Sponsored ADR stock logo
GPCR
Structure Therapeutics
12/8/2025Boost Price Target$69.83$125.00Buy